Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas
Abstract Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient’s outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients. In the current World Health Organization classification published in 2021, several new entities are recognized in pediatric-type diffuse gliomas, some of which require methylation profiling. In this review, we investigated the utility of genome-wide DNA methylation profiling in pediatric-type diffuse glioma, as well as issues in the clinical application of this assay. Furthermore, the combination of genome-wide DNA methylation profiling and other comprehensive genomic assays, which may improve diagnostic accuracy and detection of the actionable target, will be discussed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Brain tumor pathology - 40(2023), 2 vom: 01. Apr., Seite 56-65 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Otani, Yoshihiro [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Genome-wide DNA methylation profiling |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10014-023-00457-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR050089994 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR050089994 | ||
| 003 | DE-627 | ||
| 005 | 20230419064742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230419s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10014-023-00457-6 |2 doi | |
| 035 | |a (DE-627)SPR050089994 | ||
| 035 | |a (SPR)s10014-023-00457-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Otani, Yoshihiro |e verfasserin |0 (orcid)0000-0002-1615-5125 |4 aut | |
| 245 | 1 | 0 | |a Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient’s outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients. In the current World Health Organization classification published in 2021, several new entities are recognized in pediatric-type diffuse gliomas, some of which require methylation profiling. In this review, we investigated the utility of genome-wide DNA methylation profiling in pediatric-type diffuse glioma, as well as issues in the clinical application of this assay. Furthermore, the combination of genome-wide DNA methylation profiling and other comprehensive genomic assays, which may improve diagnostic accuracy and detection of the actionable target, will be discussed. | ||
| 650 | 4 | |a Genome-wide DNA methylation profiling |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pediatric-type diffuse glioma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pediatric brain tumor |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Satomi, Kaishi |4 aut | |
| 700 | 1 | |a Suruga, Yasuki |4 aut | |
| 700 | 1 | |a Ishida, Joji |4 aut | |
| 700 | 1 | |a Fujii, Kentaro |4 aut | |
| 700 | 1 | |a Ichimura, Koichi |4 aut | |
| 700 | 1 | |a Date, Isao |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain tumor pathology |d Tōkyō : Springer, 1997 |g 40(2023), 2 vom: 01. Apr., Seite 56-65 |w (DE-627)SPR008018421 |w (DE-600)2237460-7 |x 1861-387X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:2 |g day:01 |g month:04 |g pages:56-65 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10014-023-00457-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 2 |b 01 |c 04 |h 56-65 | ||